Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Kanapathy Pillai, Shant Kishen ^a   Tay, Annie ^a   Nair, Suseela ^b   Leong, Chee Onn ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b Gleneagles Hospital Kuala Lumpur   (Malaysia)

Author keywords

Basal like; c Kit; CK5 6; EGFR; Triple negative breast cancers

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; ASIAN; BASAL LIKE BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALAYSIA; METASTASIS; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

EID: 84866547970     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-18     Document Type: Article

References (44)

1. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Proc Natl Acad Sci U S A 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
2. The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response. Loi S, Piccart M, Sotiriou C, Crit Rev Oncol Hematol 2007 61 3 187 194 10.1016/j.critrevonc.2006.09.005 17088071 (Pubitemid 46329428)
3. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. N Engl J Med 2002 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
4. Repeated observation of breast tumor subtypes in independent gene expression data sets. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Proc Natl Acad Sci U S A 2003 100 14 8418 8423 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
5. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Sotiriou C, Piccart MJ, Nat Rev Cancer 2007 7 7 545 553 10.1038/nrc2173 17585334 (Pubitemid 46985399)
6. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW, J Clin Invest 2007 117 5 1370 1380 10.1172/JCI30866 17446929 (Pubitemid 46718425)
7. Mutant p53 mediates survival of breast cancer cells. Lim LY, Vidnovic N, Ellisen LW, Leong CO, Br J Cancer 2009 101 9 1606 1612 10.1038/sj.bjc.6605335 19773755
8. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Clin Cancer Res 2004 10 16 5367 5374 10.1158/1078-0432.CCR-04-0220 15328174 (Pubitemid 39100473)
9. Triple negative tumours: a critical review. Reis-Filho JS, Tutt AN, Histopathology 2008 52 1 108 118 18171422 (Pubitemid 350265179)
10. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al. Clin Cancer Res 2005 11 16 5678 5685 10.1158/1078-0432.CCR-04-2421 16115903 (Pubitemid 41170290)
11. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW, Breast Cancer Res Treat 2009 113 2 357 370 10.1007/s10549-008-9926-3 18324472
12. Race, breast cancer subtypes, and survival in the Carolina breast cancer study. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. JAMA 2006 295 21 2492 2502 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
13. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B, Cancer Causes Control 2009 21 3 399 409 20024610
14. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH, Mod Pathol 2009 23 1 123 133 19855377
15. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G, Hum Pathol 2006 37 9 1217 1226 10.1016/j.humpath.2006.04.015 16938528 (Pubitemid 44286991)
16. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, et al. J Clin Oncol 2010 28 7 1145 1153 10.1200/JCO.2009.22.4725 20100965
17. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W, Breast Cancer Res 2012 13 1 15
18. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF, J Clin Oncol 2009 27 8 1323 1333 10.1200/JCO.2007.14.8197 19204209
19. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM, Mod Pathol 2006 19 2 264 271 10.1038/modpathol.3800528 16341146 (Pubitemid 43117611)
20. MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Aleskandarany MA, Rakha EA, Macmillan RD, Powe DG, Ellis IO, Green AR, Breast Cancer Res Treat 2010 127 3 591 599 20623333
21. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel «paraffin»-reactive MIB1 antibody. Weidner N, Moore DH 2nd, Vartanian R, Hum Pathol 1994 25 4 337 342 10.1016/0046-8177(94)90140-6 8163266 (Pubitemid 24151117)
22. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y, Histopathology 2006 48 6 674 682 10.1111/j.1365-2559.2006.02402.x 16681683
23. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY, BMC Cancer 2008 8 307 10.1186/1471-2407-8-307 18947390
24. Molecular portraits of human breast tumours. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Nature 2000 406 6797 747 752 10.1038/35021093 10963602
25. The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Rakha EA, Aleskandarany M, El-Sayed ME, Blamey RW, Elston CW, Ellis IO, Lee AH, Eur J Cancer 2009 45 10 1780 1787 10.1016/j.ejca.2009.02.014 19286369
26. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO, Clin Cancer Res 2008 14 5 1368 1376 10.1158/1078-0432.CCR-07-1658 18316557 (Pubitemid 351413917)
27. Hallmarks of 'BRCAness' in sporadic cancers. Turner N, Tutt A, Ashworth A, Nat Rev Cancer 2004 4 10 814 819 10.1038/nrc1457 15510162 (Pubitemid 39331153)
28. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. N Engl J Med 2001 344 11 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
29. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ, Breast Cancer Res 2009 11 3 31 10.1186/bcr2261 19463150
30. How basal are triple-negative breast cancers? Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D, Int J Cancer 2008 123 1 236 240 10.1002/ijc.23518 18398844 (Pubitemid 351705215)
31. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, Andre F, Ann Oncol 2007 18 7 1285 1286 10.1093/annonc/mdm360 17675400 (Pubitemid 47244379)
32. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V, Cancer 2007 109 9 1721 1728 10.1002/cncr.22618 17387718 (Pubitemid 46668532)
33. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM, Clin Cancer Res 2007 13 8 2329 2334 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
34. Triple-negative breast cancer: therapeutic options. Cleator S, Heller W, Coombes RC, Lancet Oncol 2007 8 3 235 244 10.1016/S1470-2045(07)70074-8 17329194 (Pubitemid 46291713)
35. Triple-negative breast cancer: clinical features and patterns of recurrence. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA, Clin Cancer Res 2007 13 15 Pt 1 4429 4434 17671126 (Pubitemid 47219710)
36. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D, J Clin Oncol 2006 24 36 5652 5657 10.1200/JCO.2006.06.5664 17116942 (Pubitemid 46631305)
37. Prognostic markers in triple-negative breast cancer. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO, Cancer 2007 109 1 25 32 10.1002/cncr.22381 17146782 (Pubitemid 46120191)
38. Clinical characteristics of triple-negative breast cancer: experience in an Asian developing country. Tan GH, Taib NA, Choo WY, Teo SH, Yip CH, Asian Pac J Cancer Prev 2009 10 3 395 398 19640180
39. An analysis of predictive biomarkers in routine histopathological reporting of infiltrating ductal breast carcinoma in a tertiary hospital in Malaysia with a focus on limitations and directions for future development. Teoh KH, Looi LM, Sabaratnam S, Cheah PL, Nazarina AR, Mun KS, Malays J Pathol 2011 33 1 35 42 21874750
40. Clinicopathological analyses of triple negative breast cancer using surveillance data from the registration committee of the Japanese breast cancer society. Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T, Breast Cancer 2009 17 2 118 124 19466512
41. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Tian XS, Cong MH, Zhou WH, Zhu J, Chen YZ, Liu Q, Onkologie 2008 31 11 610 614 10.1159/000162288 19145094
42. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Brenton JD, Carey LA, Ahmed AA, Caldas C, J Clin Oncol 2005 23 29 7350 7360 10.1200/JCO.2005.03.3845 16145060 (Pubitemid 46202348)
43. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ, Breast Cancer Res 2007 9 5 65 10.1186/bcr1771 17910759 (Pubitemid 350187481)
44. Triple-negative and basal-like breast cancer: implications for oncologists. Lachapelle J, Foulkes WD, Curr Oncol 2011 18 4 161 164 21874112